We are live on ! Find out more
NERM

New England Research & Management Portfolio holdings

AUM $257M
1-Year Est. Return 25.66%
This Fund
S&P 500
This Quarter Est. Return
-2.57%
1 Year Est. Return
+25.66%
3 Year Est. Return
+56.38%
5 Year Est. Return
+58.71%
10 Year Est. Return
+176.32%
AUM
$193M
AUM Growth
-$14M
Cap. Flow
-$5.91M
Cap. Flow %
-3.07%
Top 10 Hldgs %
24.03%
Holding
208
New
31
Increased
43
Reduced
64
Closed
52

Top Sells

Rank Stock Value
1
PLD
PROLOGIS
PLD
+$2.01M
2
ADI icon
Analog Devices
ADI
+$1.86M
3
HLT
HILTON HOTELS CORP
HLT
+$1.83M
4
V icon
Visa
V
+$1.78M
5
CCI icon
Crown Castle
CCI
+$1.63M

Sector Composition

Rank Sector Weight
1 Industrials 21.29%
2 Healthcare 15.89%
3 Financials 14.27%
4 Technology 13.65%
5 Consumer Staples 12.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KNX icon
101
Knight Transportation
KNX
$11.1B
$530K 0.27%
10,495
-400
-4% -$22K
VNO icon
102
Vornado Realty Trust
VNO
$6.45B
$528K 0.27%
+11,645
New +$510K
CVS icon
103
CVS Health
CVS
$121B
$526K 0.27%
5,195
+50
+1% +$5.25K
COF icon
104
Capital One
COF
$127B
$522K 0.27%
3,975
-150
-4% -$21.9K
CCJ icon
105
Cameco
CCJ
$39.7B
$509K 0.26%
+17,475
New +$410K
ADI icon
106
Analog Devices
ADI
$175B
$508K 0.26%
3,077
-11,470
-79% -$1.86M
WSM icon
107
Williams-Sonoma
WSM
$26.1B
$505K 0.26%
6,970
-380
-5% -$28.8K
CTRA
108
DELISTED
Coterra Energy
CTRA
$504K 0.26%
+18,675
New +$436K
BA icon
109
Boeing
BA
$166B
$502K 0.26%
2,620
+480
+22% +$96.3K
SUM
110
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
$502K 0.26%
16,425
GSK icon
111
GSK
GSK
$100B
$496K 0.26%
9,108
+28
+0.3% +$1.52K
WY icon
112
Weyerhaeuser
WY
$16.1B
$493K 0.26%
+13,020
New +$516K
ALB icon
113
Albemarle
ALB
$13.4B
$487K 0.25%
2,200
-450
-17% -$95K
PCAR icon
114
PACCAR
PCAR
$64.5B
$482K 0.25%
8,205
-18,765
-70% -$1.15M
DD icon
115
DuPont de Nemours
DD
$17.3B
$481K 0.25%
+5,204
New +$508K
AQUA
116
DELISTED
Evoqua Water Technologies Corp. Common Stock
AQUA
$478K 0.25%
10,175
-725
-7% -$30.9K
GE icon
117
GE Aerospace
GE
$319B
$477K 0.25%
8,366
EXPE icon
118
Expedia Group
EXPE
$35.2B
$460K 0.24%
+2,350
New +$440K
WBA
119
DELISTED
Walgreens Boots Alliance
WBA
$458K 0.24%
10,240
-350
-3% -$17.2K
EMR icon
120
Emerson Electric
EMR
$82B
$443K 0.23%
4,518
SWKS icon
121
Skyworks Solutions
SWKS
$13.5B
$422K 0.22%
3,165
+185
+6% +$26K
LLY icon
122
Eli Lilly
LLY
$1.01T
$411K 0.21%
1,434
+124
+9% +$31.9K
CTAS icon
123
Cintas
CTAS
$79.6B
$393K 0.2%
3,700
-100
-3% -$9.73K
LYB icon
124
LyondellBasell Industries
LYB
$21.1B
$368K 0.19%
3,575
-200
-5% -$19.9K
VLO icon
125
Valero Energy
VLO
$114B
$360K 0.19%
+3,550
New +$308K

Similar funds

New England Research & Management's Q1 2022 Portfolio in Review

As of Q1 2022, New England Research & Management held 208 positions worth $193M, down 6.8% from $207M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

New England Research & Management withdrew a net $5.91M in Q1 2022, closing 52 positions and reducing 64 holdings. Its most notable exit was PROLOGIS, an estimated $2.01M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 21% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.

Against the trend, New England Research & Management opened a new position in C.H. Robinson worth $2.05M.

  • New England Research & Management's largest Q1 2022 buy was C.H. Robinson: 19,025 shares worth $2.05M.
  • New England Research & Management added most to Prosperity Bancshares in Q1 2022, an estimated $1.77M increase.
  • New England Research & Management's biggest Q1 2022 reduction was Analog Devices, cutting an estimated $1.86M.
  • New England Research & Management fully exited PROLOGIS in Q1 2022, selling an estimated $2.01M.
  • New England Research & Management's ten largest holdings make up 24% of its $193M portfolio in Q1 2022.
  • New England Research & Management opened 31 new positions and closed 52 in Q1 2022.
  • New England Research & Management's portfolio value fell 6.8% quarter-over-quarter to $193M.

Based on New England Research & Management's 13F filing for Q1 2022, filed 20 Apr 2022.